Amneal Pharmaceuticals, Inc. Class A Common Stock Earnings Dividend

Amneal Pharmaceuticals, Inc. Class A Common Stock’s revenue jumped 3.9% since last year same period to $722.52Mn in the Q1 2026. On a quarterly growth basis, Amneal Pharmaceuticals, Inc. Class A Common Stock has generated -11.27% fall in its revenue since last 3-months.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s net profit jumped 412.48% since last year same period to $62.5Mn in the Q1 2026. On a quarterly growth basis, Amneal Pharmaceuticals, Inc. Class A Common Stock has generated 78.18% jump in its net profits since last 3-months.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s net profit margin jumped 393.26% since last year same period to 8.65% in the Q1 2026. On a quarterly growth basis, Amneal Pharmaceuticals, Inc. Class A Common Stock has generated 100.81% jump in its net profit margins since last 3-months.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s price-to-earnings ratio after this Q1 2026 earnings stands at 46.35.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.24 - a 23.52% jump from last quarter’s estimates.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s earning per share (EPS) estimates for the current year stand at 0.24.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s earning per share (EPS) jumped 28.57% since last year same period to 0.27 in the Q1 2026. This indicates that the Amneal Pharmaceuticals, Inc. Class A Common Stock has generated 28.57% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Amneal Pharmaceuticals, Inc. Class A Common Stock’s return on assets (ROA) stands at 0.08.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Amneal Pharmaceuticals, Inc. Class A Common Stock’s return on equity (ROE) stands at -8.81.